IND application submitted to the U.S. FDA for UTRxM1-18 for targeting c-MYC driven cancers
“This IND submission is a seismic leap forward and offers patients an option where there are none,” said Dr. Awah. “Our technology’s unique ability to therapeutically degrade mRNA transcripts redefines what’s possible in biotech. We’re not just innovating—we’re rewriting the future of cancer and disease,” said Dr David T Asuzu MD, PhD, MPH, Chief Medical Officer (Adult Cancers), UTRx Inc. “The validation data supports the technological abilities of engineering mRNA stability elements on the 3’UTR of oncogenes for therapeutic use,” said Dr. Kevin Struhl PhD, co-inventor of the technology and advisor to UTRx Inc, and Professor of Biological Chemistry and Molecular Pharmacology at Harvard University.
Share:
More News
“FDA clearance of the IND for ORM-1153 is an important milestone for Orum, bringing another first-in-class DAC into the clinic and extending our approach into CD123-expressing hematologic malignancies,” said Olaf Christensen, M.D., Chief Medical Officer of Orum Therapeutics. “By combining cell-selective delivery with targeted protein degradation in a single molecule,
“We are excited to expand our clinical collaboration with Roche to evaluate a second KRAS combination with potential best-in-class MTA-cooperative PRMT5 inhibitor IDE892 for pancreatic cancer patients, where there remains a high unmet medical need. IDEAYA is advancing multiple rational combination strategies for the IDE892 program, including with MAT2A inhibitor
“These encouraging initial safety observations represent an important first step in the clinical evaluation of ZI-MA4-1 and our TCR-NK platform” said Namir Hassan, Chief Executive Officer of Zelluna. “The first patient received all three planned doses, and the independent committee’s recommendation enables us to continue recruitment at the first dose
“Receiving FTD is an important milestone for ERAS-0015 and reflects the urgent need for new therapies for patients with metastatic pancreatic cancer,” said Jonathan E. Lim, M.D., Erasca’s chairman, CEO, and co-founder. “Together with the encouraging clinical activity and favorable tolerability observed to date, this FTD helps to position us